Key Takeaways
- Holoclara is developing therapeutics from worm secretions, aiming to modulate the immune system rather than suppress it.
- The company is conducting a Phase I clinical trial for HC002, a worm-derived small molecule targeting eosinophilic esophagitis, with promising implications for broader immunology and inflammation treatments.
- Holoclara's proprietary discovery engine and 'worm atlas' could lead to a new class of medicines, addressing various clinical concerns and potentially transforming patient care.
As Eureka moments go, Andrea Choe’s was very 21st century. Choe is the CEO and co-founder of Holoclara, a biotech start-up investigating a new class of medicines derived from intestinal worms
“Someone sent me this podcast about a guy who goes to Africa and walks around barefoot trying to get hookworms, on purpose, to treat his untreatable asthma,” Choe told In Vivo
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?